Reactome | PKR inhibitors bind PKR

PKR inhibitors bind PKR

Stable Identifier

R-HSA-9836702

Type

Reaction [binding]

Species

Homo sapiens

Compartment

cytosol

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Only a few FDA-approved small molecule inhibitors of PKR are currently available (reviewed by Wu, 2021). Sunitinib is a Type-1 kinase inhibitor, approved in 2006 for the treatment of cancer (Jha et al, 2011; Jha et al, 2013). Luteolin is a ubiquitous flavonoid with antimalarial activity (Dabo et al, 2017).

Literature References

PubMed ID	Title	Journal	Year
37127961	Inhibition of RNA-binding proteins with small molecules Wu, P	Nat Rev Chem	2020
29170442	Inhibition of the inflammatory response to stress by targeting interaction between PKR and its cellular activator PACT Tible, M, Cassonnet, P, Hugon, J, Gatignol, A, Bigot, DJ, Maillard, P, Janvier, G, Helynck, O, Dabo, S, Mazouz, S, Hansen, MD, Collados Rodriguez, M, Munier-Lehmann, H, Patel, RC, Bellalou, J, Meurs, EF, Jacob, Y	Sci Rep	2017
21636578	Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity Silverman, RH, Sen, GC, Dong, B, Kessler, P, Polyakova, I, Dickerman, B, Jha, BK	J Biol Chem	2011
23732991	Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy Silverman, RH, Dong, B, Polyakova, I, Jha, BK, Nguyen, CT	Mol Ther	2013